What is "geovax"

GeoVax is a biotechnology company established primarily to develop an effective and safe vaccine against HIV-1. Ultimately the company is to create vaccines for many serious human diseases for which none currently exist. GeoVax is currently conducting multiple site Phase 2 Human clinical trials for HIV/AIDS preventative vaccine products following successful completion of multiple Phase 1 human clinical trials.

In 2010 GeoVax began enrolling patients in a Phase 1 therapeutic clinical trial for individuals already infected with HIV. The long-term therapeutic goal is to develop a vaccine-based mechanism to treat infected individuals that either prevents or significantly slows progression to symptomatic HIV, including AIDS, by stimulating an infected individual's immune system to resist the progression of infection. The study is being completed at the AIDS Research Consortium of Atlanta.